Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 4/20 | 0.50 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.50 |
| ▸ | HTR2C | P28335 | 5/20 | 0.44 |
| ▸ | HTR2B | P41595 | 5/20 | 0.44 |
| ▸ | HTR2A | P28223 | 4/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29312174 | 1.00 | CRBN (0.50) | CRBNDDB1HTR2CHTR2BHTR2A | |
| SCHEMBL845542 | 0.88 | CRBN (0.51) | CRBNDDB1HTR2CHTR2BHTR2A | |
| SCHEMBL20128632 | 0.88 | CRBN (0.51) | CRBNDDB1HTR2CHTR2BHTR2A | |
| SCHEMBL20128631 | 0.88 | CRBN (0.51) | CRBNDDB1HTR2CHTR2BHTR2A | |
| SCHEMBL21391303 | 0.78 | CRBN (0.60) | CRBNDDB1ALDH1A1 | |
| SCHEMBL21391302 | 0.78 | CRBN (0.60) | CRBNDDB1ALDH1A1 | |
| SCHEMBL17552856 | 0.77 | CRBN (0.72) | CRBNDDB1ALDH1A1 | |
| SCHEMBL5515897 | 0.77 | CRBN (0.72) | CRBNDDB1ALDH1A1 | |
| SCHEMBL17169674 | 0.77 | CRBN (0.72) | CRBNDDB1ALDH1A1 | |
| SCHEMBL30184407 | 0.77 | CRBN (0.72) | CRBNDDB1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | CRBN 5/4885DDB1 594/4885HTR2C 3949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.